(MRNA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of (MRNA)
Historical Stock Splits
If you bought 1 share of MRNA before July 22, 2010, you'd have 0.00 shares today.
Execution Date | Split Amount |
---|---|
August 3, 2017 | 1-for-10 (Reverse Split) |
December 23, 2011 | 1-for-10 (Reverse Split) |
July 22, 2010 | 1-for-4 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $-1.31 Billion |
Net Cash Flow From Operating Activities, Continuing | $-3.21 Billion |
Net Cash Flow From Financing Activities | $-50.00 Million |
Net Cash Flow From Financing Activities, Continuing | $-50.00 Million |
Net Cash Flow From Investing Activities, Continuing | $1.95 Billion |
Net Cash Flow From Operating Activities | $-3.21 Billion |
Net Cash Flow | $-1.31 Billion |
Net Cash Flow From Investing Activities | $1.95 Billion |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss | $-2.22 Billion |
Income/Loss From Continuing Operations Before Tax | $-2.35 Billion |
Operating Expenses | $6.12 Billion |
Costs And Expenses | $7.77 Billion |
Diluted Average Shares | $782.00 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-2.22 Billion |
Income Tax Expense/Benefit | $-129.00 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Gross Profit | $3.43 Billion |
Revenues | $5.08 Billion |
Basic Average Shares | $768.00 Million |
Basic Earnings Per Share | $5.82 |
Net Income/Loss Attributable To Parent | $-2.22 Billion |
Income/Loss From Continuing Operations After Tax | $-2.22 Billion |
Diluted Earnings Per Share | $5.82 |
Research and Development | $4.83 Billion |
Cost Of Revenue | $1.65 Billion |
Benefits Costs and Expenses | $7.43 Billion |
Other Operating Expenses | $1.29 Billion |
Income/Loss From Equity Method Investments | $-62.00 Million |
Income/Loss Before Equity Method Investments | $-2.29 Billion |
Operating Income/Loss | $-2.69 Billion |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Assets | $6.14 Billion |
Equity Attributable To Parent | $11.93 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Liabilities | $2.20 Billion |
Assets | $15.80 Billion |
Other Current Liabilities | $1.58 Billion |
Wages | $244.00 Million |
Other Current Assets | $9.25 Billion |
Noncurrent Liabilities | $1.68 Billion |
Equity | $11.93 Billion |
Accounts Payable | $373.00 Million |
Liabilities And Equity | $15.80 Billion |
Inventory | $412.00 Million |
Current Assets | $9.67 Billion |
Liabilities | $3.88 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to (MRNA)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.